Global Leading Market Research Publisher QYResearch announces the release of its latest report “HMO Infant Formula – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global HMO Infant Formula market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for HMO Infant Formula was estimated to be worth US4,236millionin2025andisprojectedtoreachUS4,236millionin2025andisprojectedtoreachUS 8,615 million by 2032, growing at a CAGR of 10.7% from 2026 to 2032. Human milk oligosaccharides (HMOs) are the third most abundant component in breast milk and one of the most important components in breast milk. It is precisely because of the existence of HMOs that breastfeeding has become the gold standard for infant nutrition. The latest research shows that HMOs can effectively enhance the benefits of breastfeeding, such as strengthening the immune system and promoting healthy brain development. In addition, HMOs can promote intestinal development, improve intestinal resilience, and promote the balance of intestinal microbiota. HMO is particularly important in improving the health and nutritional needs of infants and young children. Since infant formula is mainly made from cow and goat milk, and the content of HMO in cow and goat milk is very low, adding HMO to infant formula is more in line with breast milk nutrition and can better protect the healthy growth of babies. Despite these proven benefits, infant formula manufacturers face two persistent pain points: high production costs for HMO ingredients (2′-fucosyllactose, 3-fucosyllactose, lacto-N-neotetraose), and regulatory approval complexity for new HMO strains (requiring substantial equivalence studies and safety assessments in each market). This report addresses these challenges by providing a data-driven roadmap for formulating human milk oligosaccharides (HMOs)-enriched products, optimizing breast milk mimicry formula nutritional profiles, and navigating the complex regulatory landscape for infant gut microbiome-supporting ingredients.
Global key players of HMO Infant Formula include Nestlé (Wyeth Nutrition), Danone (Aptamil), FrieslandCampina (Friso), Abbott, Mead Johnson (Reckitt), etc. The top five players hold a share about 94%. Americas is the world’s largest market for HMO Infant Formula and holds a share about 58%, followed by Europe and Asia-Pacific, with share about 28% and 13%, separately. In terms of product type, 2′-FL is the largest segment, accounting for a share about 96%. In terms of application, Online Channel is the largest field with a share about 33%.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5514036/hmo-infant-formula
1. Industry Context: Why HMO Infant Formula Is the Fastest-Growing Premium Segment
Over the past 18 months, three converging factors have accelerated the HMO infant formula market. First, consumer awareness of HMOs has increased dramatically: 68% of parents in 2025 recognized “HMO” as a beneficial ingredient, up from 35% in 2022 (driven by social media and pediatrician recommendations). Second, clinical evidence has expanded: over 50 human studies now support HMO benefits for immunity, gut health, and cognitive development. Third, regulatory approvals have broadened: the EU (2023), US FDA (2024), China (2024), and Australia (2025) have approved multiple HMO strains (2′-FL, LNnT, 3-FL, 6′-SL, 3′-SL).
However, the industry faces challenges: HMO ingredients cost USD 30-60 per kilogram (vs. USD 2-5 for standard prebiotics like GOS/FOS), significantly raising formula prices (premium of 30-50% over standard formula). The latest generation of HMO production uses microbial fermentation (E. coli or yeast strains) rather than chemical synthesis, reducing costs by 40-50% since 2022.
2. Product Type Segmentation and Market Dynamics (2025–2026 H1 Data)
Based on proprietary tracking across 20 infant formula brands and 15 national markets (Q1–Q2 2026), the market is segmented by HMO strain:
- 2′-Fucosyllactose (2′-FL) Dominant Formulas: Represented 96% of HMO infant formula market value in 2025. 2′-FL is the most abundant HMO in breast milk (20-30% of total HMOs) and the most studied. Found in nearly all HMO-fortified formulas (typical concentration: 0.5-2.0 g/L). Key benefits: anti-adhesive effect against pathogens (e.g., Campylobacter, norovirus), bifidogenic effect (stimulates Bifidobacterium growth), and immune modulation. Infant gut microbiome development supported by 2′-FL supplementation has been shown to reduce colic (24% reduction) and infections (30% reduction in respiratory tract infections, 2025 meta-analysis).
- Multi-HMO Formulas (2′-FL + LNnT + 3-FL + 6′-SL + others): Represented 4% of market value (growing at 25% CAGR). Premium products mimicking the diversity of breast milk (which contains 150-200 different HMOs). Current technology can produce 5-8 HMO strains via fermentation; more complex blends are in development. Price premium: 20-40% above 2′-FL-only formulas. Key players: Nestlé (Illuma with 2 HMOs), Danone (Aptamil with 3 HMOs), Abbott (Similac with 5 HMOs).
Key Data Point (H1 2026): HMO production capacity has expanded significantly: global fermentation capacity for 2′-FL reached 12,000 metric tons annually (up from 5,000 tons in 2022). Average 2′-FL price to formula manufacturers: USD 35-45/kg (down from USD 70-90 in 2022). This has enabled HMO inclusion in mid-tier formulas, not just premium.
3. Deep Dive: Regional Market Dynamics – Americas vs. Europe vs. Asia-Pacific
A unique contribution of this analysis is the segmentation by geography, which reveals divergent regulatory, consumer preference, and pricing dynamics:
- Americas (58% market share, 8-9% CAGR): Largest and most mature HMO infant formula market. US leads (over 70% of Americas sales), followed by Brazil and Mexico. Key drivers: strong pediatrician recommendation (76% of US pediatricians recommend HMO formula), direct-to-consumer marketing (social media, influencer campaigns), and high formula prices (USD 30-50 per can, vs. USD 15-25 for standard). Immune system development messaging resonates strongly with US parents. FDA has approved 2′-FL, LNnT, 3-FL, 6′-SL, and 3′-SL; additional strains under review.
Case Study: Abbott Nutrition launched Similac 360 Total Care (with 2′-FL, LNnT, and 3-FL) in the US in 2024, positioning it as “closest to breast milk.” Within 12 months, it captured 22% of the US premium formula market (USD 800 million annual sales). Consumer surveys indicated 73% of buyers cited “immunity support” as primary reason. Abbott’s HMO ingredient supply (from fermentation partner Inbiose) cost USD 38/kg, contributing 12% of formula production cost.
- Europe (28% market share, 12% CAGR): Fastest-growing region. Key drivers: EU regulatory approvals (EFSA positive opinions) enabled rapid market entry, strong consumer preference for “scientific” infant nutrition, and high willingness to pay for premium. Germany, France, and UK lead. Danone (Aptamil) holds dominant share (40-45%). EU restricts HMO health claims (cannot claim “reduces infection” without extensive dossier), so marketing focuses on “supports natural defenses” and “close to breast milk.”
- Asia-Pacific (13% market share, 15-16% CAGR): Fastest-growing region on percentage basis but smaller absolute size. China leads, but HMO approval (2024) was later than US/EU. Key drivers: rising middle class (premium formula demand), declining breastfeeding rates (urbanization), and Daigou (cross-border) channel for imported HMO formula (Nestlé, Danone, FrieslandCampina). Domestic Chinese brands (Yili, Ausnutria) are launching HMO formulas using imported HMO ingredients due to local production approval delays. Japan and South Korea are small but growing markets (5-6% formula sales with HMO).
4. Key Market Players and Strategic Positioning (2026 Update)
The HMO infant formula market is highly concentrated, with top 5 players holding 94% share:
- Nestlé (Wyeth Nutrition – Switzerland/USA): Holds an estimated 32% share of global HMO infant formula market. Flagship brands: Illuma (premium, 2′-FL + LNnT) and S-26 (mid-tier, 2′-FL only). Key differentiators: largest HMO clinical trial program (15+ published studies), global manufacturing footprint (Switzerland, Ireland, China, Singapore), and aggressive China cross-border strategy. Nestlé has invested USD 300 million in HMO fermentation capacity (joint venture with Glycom).
- Danone (Aptamil – France): Holds 28% share. Flagship brand: Aptamil Profutura (with 2′-FL + LNnT + 3-FL). Danone’s key differentiator is European authenticity (perceived as higher quality in Asia) and strong medical detailing (pediatrician recommendation program). Danone recently launched Aptamil with 5 HMO strains in Germany (2026). Manufacturing in Netherlands, Germany, and China.
- Abbott (USA): Holds 18% share. Flagship: Similac 360 Total Care (2′-FL + LNnT + 3-FL). Strongest in US market (40% share of HMO formula). Differentiators: “360 Total Care” messaging (immunity, brain, digestion), large-scale consumer marketing (TV, digital, influencer), and pediatrician sampling programs. Manufacturing in Ireland, US, and China.
- FrieslandCampina (Friso – Netherlands): Holds 10% share. Flagship: Friso Prestige (with 2′-FL). Differentiators: “Dutch soil” quality perception (strong in China), vertically integrated dairy (own farms), and competitive pricing (10-15% below Nestlé/Danone). Strongest in Asia-Pacific (China, Vietnam, Indonesia).
- Mead Johnson (Reckitt – USA): Holds 6% share. Flagship: Enfamil NeuroPro with HMO (2′-FL only). Differentiators: neuroscience focus (“NeuroPro” branding), strong US retail presence, and lower price point (USD 28-35 per can vs. USD 35-45 for Similac/Aptamil).
- Biostime (China/Hong Kong) and Yili Group (Ausnutria Dairy – China): Collectively hold 4% share, growing in domestic China. Chinese brands using imported HMO ingredients (from Glycom, Inbiose, Jennewein). Price point: USD 40-60 per can (premium positioning, leveraging “domestic brand for Chinese babies” messaging).
Segment by Type:
- 2′-Fucosyllactose (2′-FL) Dominant Formulas
- Others (Multi-HMO formulas: 2′-FL + LNnT, 2′-FL + LNnT + 3-FL, 5+ HMO blends)
Segment by Distribution Channel:
- Online Channel (e-commerce, brand websites, cross-border platforms like Tmall Global, JD Worldwide)
- Specialty Store (baby stores, pharmacies, pediatric clinics)
- Supermarket (hypermarkets, grocery chains, mass merchants)
- Others (hospital, maternity ward sampling; subscription services)
5. Technical Hurdles and Regulatory Trends (2025–2026 Updates)
Despite rapid growth, four persistent challenges remain:
- HMO Production Cost and Fermentation Yield: HMOs are produced via microbial fermentation (engineered E. coli or yeast), then purified (chromatography, membrane filtration). Current yields: 80-120 g/L for 2′-FL (improved from 30-50 g/L in 2020). Lower-yield strains (LNnT, 3-FL, 6′-SL) cost 2-3x more. The industry is investing in strain engineering (CRISPR) and downstream processing to reduce costs to USD 20-30/kg by 2028.
- Dosage and Efficacy Evidence: While 2′-FL has strong evidence at 1.5-2.0 g/L, optimal dosages for other strains are less established. Multi-HMO formulas combine multiple strains at lower individual levels (e.g., 1.0 g/L 2′-FL + 0.5 g/L LNnT + 0.3 g/L 3-FL). Breast milk mimicry formula requires research on synergistic effects; regulators demand clinical trials for each new combination.
- Regulatory Harmonization Gap: Each region has different approved strains, labeling requirements, and health claim rules:
- US (FDA): GRAS notices filed for 2′-FL (2016), LNnT (2019), 3-FL (2022), 6′-SL (2023), 3′-SL (2024). No prior approval needed for new strains if GRAS self-determination; FDA can object.
- EU (EFSA): Novel Food authorization required for each strain. Approved: 2′-FL (2016), LNnT (2019), 3-FL (2023), 6′-SL (2023). Health claims (Article 13.5) require submission of clinical dossier; only structure/function claims allowed currently.
- China (CFSA): National Health Commission (NHC) approval required. 2′-FL approved 2024 (first HMO). Other strains under review. Imported HMO formula (from Nestlé, Danone, FrieslandCampina) currently dominates Chinese market.
- Japan (MHLW), Korea (MFDS), Australia (FSANZ): All have approved 2′-FL and LNnT; other strains case-by-case.
- Consumer Education and Premium Justification: HMO formula costs 30-50% more than standard formula. Parents need convincing that HMOs provide tangible benefits (fewer sick days, less colic, better digestion). Marketing claims are regulated (cannot claim “prevents infections” in most markets). The industry uses surrogate endpoints (“supports immune system,” “helps beneficial bacteria grow”). Online reviews and social proof (parent testimonials) are crucial marketing channels.
6. Exclusive Market Forecast Summary (2026–2032)
Based on cross-referenced regression modeling (global birth rates, formula consumption, premiumization trends, and regulatory approvals), this report concludes:
- Most optimistic scenario: Total market reaches USD 10.5 billion by 2032 (CAGR 13.8%), driven by rapid HMO approval in China (5+ strains by 2028), breakthrough low-cost multi-HMO production (USD 25/kg by 2028), and mandatory HMO inclusion in government-subsidized formula programs (EU, China). Multi-HMO segment reaches 20-25% market share.
- Baseline scenario (most likely): Total market reaches USD 8.6 billion by 2032 (CAGR 10.7%). 2′-FL remains dominant (90-92% of HMO formula market). Asia-Pacific grows fastest (14-15% CAGR), reaching 20-22% market share by 2032. Average formula selling price increases 3-4% annually (premiumization + HMO ingredient costs). Online channel grows to 35-38% share.
- Downside risk: If global birth rates decline faster than forecast (currently 2.2 children/woman global average, trending to 2.0 by 2032) and consumers trade down to standard formula during economic downturns, HMO formula growth could slow to 7-8% CAGR, reaching USD 6.5 billion by 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
